Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 11/20 | 0.49 |
| ▸ | RARG | P13631 | 11/20 | 0.49 |
| ▸ | RARA | P10276 | 9/20 | 0.49 |
| ▸ | ERN1 | O75460 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174449 | 0.97 | MEN1 (0.51) | MEN1KMT2ATHRBRECQLNR2E1 | |
| Methane SCHEMBL16147650 | 0.86 | RARB (0.56) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL1250065 | 0.75 | ACMSD (0.57) | MEN1KMT2ATHRBRECQLNR2E1 | |
| Methane SCHEMBL16146729 | 0.74 | RARB (0.60) | MEN1KMT2ARARBRARGRARA | |
| SCHEMBL14157072 | 0.72 | MIF (0.57) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL5047765 | 0.72 | RARB (0.60) | MEN1KMT2ARARBRARGRARA | |
| SCHEMBL3020401 | 0.71 | ESR1 (0.67) | MEN1KMT2ARARBRARGRARA | |
| SCHEMBL20979999 | 0.70 | MEN1 (0.57) | MEN1KMT2ATHRBRECQLNR2E1 | |
| SCHEMBL29049592 | 0.70 | RARB (0.62) | MEN1KMT2ARARBRARGRARA | |
| SCHEMBL30526912 | 0.70 | RARB (0.62) | MEN1KMT2ARARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4066826-B1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4066826-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS FOR MUSCLE REPAIR AND REGENERATION | Thomas Jefferson University (US) | 2022-10-05 | — | — | EP | claimed |
| US-11433039-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2022-09-06 | — | — | US | claimed |
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | NORTHWESTERN UNIVERSITY | 2022-01-20 | — | — | US | claimed |
| US-11135236-B2 | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity | NORTHWESTERN UNIVERSITY (US) | 2021-10-05 | — | — | US | claimed |
| EP-2613776-B1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | UNIV JEFFERSON (US) | 2020-07-29 | — | — | EP | claimed |
| US-20200069620-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2020-03-05 | — | — | US | claimed |
| US-9789074-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2017-10-17 | — | — | US | claimed |
| US-20140363402-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2014-12-11 | — | — | US | claimed |
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250345316-A1 | METHODS OF INCREASING LYMPHOCYTE TRAFFICKING TO THE COLON BY STIMULATING RETINOIC ACID RECEPTORS AND ARYL HYDROCARBON RECEPTORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250108022-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2025-04-03 | — | — | US | disclosed |
| US-20240392241-A1 | METHOD FOR PRODUCING CELL MASS INCLUDING PITUITARY TISSUE AND CELL MASS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-9314439-B2 | Composition and method for muscle repair and regeneration | THOMAS JEFFERSON UNIVERSITY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20160068806-A1 | COMPOSITIONS AND METHODS FOR PRECISE PATTERNING OF POSTERIOR NEUROECTODERM FROM HUMAN PLURIPOTENT STEM CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-03-10 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20140363402-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140303223-A1 | COMPOSITION AND METHOD FOR MUSCLE REPAIR AND REGENERATION | THOMAS JEFFERSON UNIVERSITY | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12529032-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | NES, CDH1, SHH | MEN1 1044/4885KMT2A 3135/4885THRB 308/4885 |
| US-20220016148-A1 | RETINOIC ACID RECEPTOR GAMMA AGONISTS TO ATTENUATE ANTHRACYCLINE-INDUCED CARDIOTOXICITY | RARG, RXRG, RARA | MEN1 4858/4885KMT2A 3875/4885THRB 69/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MEN1 3191/4885KMT2A 3792/4885THRB 2815/4885 |
| US-11135236-B2 | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity | RARG, RXRG, RARA | MEN1 4858/4885KMT2A 3875/4885THRB 69/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | MEN1 3191/4885KMT2A 3792/4885THRB 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.